Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG). In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system. The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts. OPGL expression in T cells is induced by antigen receptor engagement, which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation. These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RANKL is produced by numerous cell types including cells of the osteoblast lineage (46,47) and activated T cells (42,48,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“T Cells express both soluble and membrane-bound forms of RANKL (49,50), and both forms are implicated in focal bone erosions associated with inflammatory arthritis (26,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“Within the developed immune system, RANKL is expressed by T cells (42), RANK is expressed by dendritic cells (49), and OPG is expressed by B lymphocytes and dendritic cells (4,70).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“However, RANK and RANKL knockout mice had normal Peyer's patches and intact splenic architecture (49,62), indicating that the development of lymph nodes and secondary lymphoid organs can be differentially regulated.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“RANKL inhibition via recombinant OPG treatment also results in marked suppression of bone erosions and osteoclasts in several rodent models, including adjuvant arthritis (26,49,177,232,233), collagen-induced arthritis (26,181,233), and TNF-mediated arthritis (136, 234).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“We show that: (1) p66 is serine phosphorylated upon treatment with hydrogen peroxide (H2O2) or irradiation with ultraviolet light; (2) ablation of p66 enhances cellular resistance to apoptosis induced by H2O2 or ultraviolet light; (3) a serinephosphorylation defective mutant of p66 cannot restore the normal stress res…”
BackgroundSelf-citationRAG-1-deficient mice have no mature B and T lymphocytes
Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., & Papaioannou, V. E. (1992) · Cell · doi:10.1016/0092-8674(92)90030-g · Cited by 2,931
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M. T., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5703 · Cited by 1,696
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Self-citationWong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Cited by
Items 301–400 of 1,007
Estrogen deficiency, T cells and bone loss
Pacifici, R. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2007.06.008 · Cited by 146
Root resorption and the OPG/RANKL/RANK system: a mini review
Tyrovola, J. B., Spyropoulos, M. N., Makou, M., & Perrea, D. N. (2008) · Journal of Oral Science · doi:10.2334/josnusd.50.367 · Cited by 170
“The role of RANKL, together with another very important protein ligand, MCSF (which binds to its receptor c-fms), is to promote osteoclast formation, fusion, differentiation, activation and survival, thus enhancing bone resorption (10-19).”
BackgroundBone marrow Th17 TNFα cells induce osteoclast differentiation, and link bone destruction to IBD
Ciucci, T., Ibáñez, L., Boucoiran, A., Birgy-Barelli, E., Pène, J., Abou-Ezzi, G., Arab, N., Rouleau, M., Hébuterne, X., Yssel, H., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-306947 · Cited by 145
Kondo, H., Guo, J., & Bringhurst, F. R. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.9.1667 · Cited by 158
Inflammation, mesenchymal stem cells and bone regeneration
Liu, H., Li, D., Zhang, Y., & Li, M. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1643-3 · Cited by 160
Schulze, J., Bickert, T., Beil, F. T., Zaiss, M. M., Albers, J., Wintges, K., Streichert, T., Klaetschke, K., Keller, J., Hissnauer, T.-N., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.269 · Cited by 143
Poubelle, P. E., Chakravarti, A., Fernandes, M. J., Doiron, K., & Marceau, A.-A. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2137 · Cited by 142
Alnaeeli, M., Penninger, J. M., & Teng, Y.-T. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3314 · Cited by 142
“Importantly, our studies and others showed that activated T cells express RANKL and mediate osteoclastogenesis (16, 17), and that blocking RANKL activity via OPG injections results in a significant reduction of bone loss in RA, PD, osteoporosis, cancerrelated bone metastasis and type 1 diabetes-associated alveolar bon…”
Self-citationLee, J.-H., Kim, B.-J., Jin, W. J., Kim, H., Ha, H., & Lee, Z. H. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1353-6 · Cited by 143
Hanada, R., Hanada, T., Sigl, V., Schramek, D., & Penninger, J. M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0749-z · Cited by 154
Self-citationOsteoporosis in Rheumatoid Arthritis: Dangerous Liaisons
Llorente, I., García-Castañeda, N., Valero, C., González-Álvaro, I., & Castañeda, S. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.601618 · Cited by 139
“In a T cell-dependent animal model of arthritis, blocking RANKL by OPG prevents bone destruction, but not inflammation (57).”
BackgroundLaBranche, T. P., Jesson, M. I., Radi, Z. A., Storer, C. E., Guzova, J. A., Bonar, S. L., Thompson, J., Happa, F. A., Stewart, Z. S., Zhan, Y., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34649 · Cited by 147
Interaction between Synovial Inflammatory Tissue and Bone Marrow in Rheumatoid Arthritis
Jimenez-Boj, E., Redlich, K., Türk, B., Hanslik-Schnabel, B., Wanivenhaus, A., Chott, A., Smolen, J. S., & Schett, G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2579 · Cited by 139
Okamoto, K., & Takayanagi, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031245 · Cited by 162
Osteoclasts; culprits in inflammatory osteolysis.
Teitelbaum, S. L. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1857 · Cited by 158
Chronic Obstructive Pulmonary Disease: A Chronic Systemic Inflammatory Disease
van Eeden, S. F., & Sin, D. D. (2007) · Respiration · doi:10.1159/000111820 · Cited by 168
“These mechanisms are similar to increased osteoclastic activity proposed in other systemic inflammatory disorders such as rheumatoid arthritis [”
BackgroundDai, S.-M., Nishioka, K., & Yudoh, K. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018481 · Cited by 152
Komine, M., Kukita, A., Kukita, T., Ogata, Y., Hotokebuchi, T., & Kohashi, O. (2001) · Bone · doi:10.1016/s8756-3282(01)00420-3 · Cited by 156
Kacena, M. A., Shivdasani, R. A., Wilson, K., Xi, Y., Troiano, N., Nazarian, A., Gundberg, C. M., Bouxsein, M. L., Lorenzo, J. A., & Horowitz, M. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301254 · Cited by 136
Caicedo, M. S., Pennekamp, P. H., McAllister, K., Jacobs, J. J., & Hallab, N. J. (2009) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32627 · Cited by 146
Hotokezaka, H., Sakai, E., Ohara, N., Hotokezaka, Y., Gonzales, C., Matsuo, K., Fujimura, Y., Yoshida, N., & Nakayama, K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21167 · Cited by 136
“RANKL was found to be expressed by T-cells [Wong et al., 1997; Josien et al., 1999; Kong et al., 1999] and B-cells [Li et al., 2000] as well as osteoblastic/stromal cells and to be essential for osteoclast differentiation.”
BackgroundSelect HIV Protease Inhibitors Alter Bone and Fat Metabolism ex Vivo
Jain, R. G., & Lenhard, J. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200069200 · Cited by 136
Kotake, S., Nanke, Y., Mogi, M., Kawamoto, M., Furuya, T., Yago, T., Kobashigawa, T., Togari, A., & Kamatani, N. (2005) · European Journal of Immunology · doi:10.1002/eji.200526141 · Cited by 136
Interleukin-6 and interleukin-11: same same but different
Garbers, C., & Scheller, J. (2013) · bchm · doi:10.1515/hsz-2013-0166 · Cited by 134
Bone Remodeling Biomarkers of Periodontal Disease in Saliva
Frodge, B. D., Ebersole, J. L., Kryscio, R. J., Thomas, M. V., & Miller, C. S. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080070 · Cited by 158
Watts, N. B., Roux, C., Modlin, J. F., Brown, J. P., Daniels, A., Jackson, S., Smith, S., Zack, D. J., Zhou, L., Grauer, A., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1755-2 · Cited by 135
T Cells Potentiate PTH-Induced Cortical Bone Loss through CD40L Signaling
Gao, Y., Wu, X., Terauchi, M., Li, J.-Y., Grassi, F., Galley, S., Yang, X., Weitzmann, M. N., & Pacifici, R. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.001 · Cited by 135
Self-citationAnticytokine therapy for osteoarthritis
Goldring, M. B. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.5.817 · Cited by 151
Redlich, K., Görtz, B., Hayer, S., Zwerina, J., Doerr, N., Kostenuik, P., Bergmeister, H., Kollias, G., Steiner, G., Smolen, J. S., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63144-6 · Cited by 134
Role of inflammation in the aging bones
Abdelmagid, S. M., Barbe, M. F., & Safadi, F. F. (2015) · Life Sciences · doi:10.1016/j.lfs.2014.11.011 · Cited by 134
Heemstra, K. A., Hamdy, N. A. T., Romijn, J. A., & Smit, J. W. A. (2006) · Thyroid · doi:10.1089/thy.2006.16.583 · Cited by 134
Kwak, H. B., Ha, H., Kim, H., Lee, J., Kim, H. S., Lee, S., Kim, H., Kim, J. Y., Kim, H., Song, Y. W., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23372 · Cited by 133
Molecular biology of bone remodelling.
Rucci, N. (2008) · PubMed Central · Cited by 272
Chen, W., Foo, S., Taylor, A., Lulla, A., Merits, A., Hueston, L., Forwood, M. R., Walsh, N. C., Sims, N. A., Herrero, L. J., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02034-14 · Cited by 150
Activation of p38 MAPK is a key step in tumor necrosis factor–mediated inflammatory bone destruction
Zwerina, J., Hayer, S., Redlich, K., Bobacz, K., Kollias, G., Smolen, J. S., & Schett, G. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21626 · Cited by 132
Osteoclasts and odontoclasts: signaling pathways to development and disease
Wang, Z., & McCauley, L. K. (2011) · Oral Diseases · doi:10.1111/j.1601-0825.2010.01718.x · Cited by 149
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
Castellano, D., Sepúlveda-Sánchez, J. M., García-Escobar, I., Rodríguez-Antolín, A., Sundlöv, A., & Cortés-Funes, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0154 · Cited by 138
Pathophysiological roles of osteoprotegerin (OPG)
Reid, P., & Holen, I. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.06.004 · Cited by 143
Regulatory roles and molecular signaling of TNF family members in osteoclasts
Feng, X. (2005) · Gene · doi:10.1016/j.gene.2005.01.014 · Cited by 152
Characterization of osteoclast precursors in human blood
Shalhoub, V., Elliott, G., Chiu, L., Manoukian, R., Kelley, M., Hawkins, N., Davy, E., Shimamoto, G., Beck, J., Kaufman, S. A., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02379.x · Cited by 131
Self-citationRole of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease
Kajiya, M., Giro, G., Taubman, M. A., Han, X., Mayer, M. P. A., & Kawai, T. (2010) · Journal of Oral Microbiology · doi:10.3402/jom.v2i0.5532 · Cited by 149
Bone Mineral Density at Time Of Clinical Diagnosis of Adult-Onset Type 1 Diabetes Mellitus
López-Ibarra, P. J., Pastor, M. M. C., Escobar‐Jiménez, F., Pardo, M. D. S., González, A. G., Luna, J. D. D., Requena, M. E. R., & Aguilar‐Diosdado, M. (2001) · Endocrine Practice · doi:10.4158/ep.7.5.346 · Cited by 130
Rutgers, M., Saris, D. B. F., Dhert, W. J. A., & Creemers, L. B. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3050 · Cited by 149
The Role of Macrophage in the Pathogenesis of Osteoporosis
Yang, D.-H., & Yang, M.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092093 · Cited by 128
“In patients with rheumatoid arthritis (RA), activated T cells can directly trigger osteoclastogenesis through RANKL/RANK/OPG pathway [46,47].”
BackgroundOsteoporosis: the current status of mesenchymal stem cell-based therapy
Phetfong, J., Sanvoranart, T., Nartprayut, K., Nimsanor, N., Seenprachawong, K., Prachayasittikul, V., & Supokawej, A. (2016) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-016-0013-1 · Cited by 136
Inflammatory and anti-inflammatory markers in plasma: from late pregnancy to early postpartum
Bränn, E., Edvinsson, Å., Punga, A. R., Poromaa, I. S., & Skalkidou, A. (2019) · Scientific Reports · doi:10.1038/s41598-018-38304-w · Cited by 140
Heme oxygenase 1 (HO‐1) regulates osteoclastogenesis and bone resorption
Zwerina, J., Tzima, S., Hayer, S., Redlich, K., Hoffmann, O., Hanslik‐Schnabel, B., Smolen, J. S., Kollias, G., & Schett, G. (2005) · The FASEB Journal · doi:10.1096/fj.05-4278fje · Cited by 127
Intercellular Cross-Talk Among Bone Cells: New Factors and Pathways
Sims, N. A., & Walsh, N. C. (2012) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0096-1 · Cited by 140
Takegahara, N., Kim, H., & Choi, Y. (2022) · Bone · doi:10.1016/j.bone.2022.116353 · Cited by 143
Bacterial-Responsive B Lymphocytes Induce Periodontal Bone Resorption
Han, X., Kawai, T., Eastcott, J. W., & Taubman, M. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.625 · Cited by 134
“RANKL is a TNF-related cytokine that has not only been reported to be involved in physiological osteoclastogenesis, but also in pathological bone loss (23, 26).”
BackgroundMethodTargeting osteoclasts with zoledronic acid prevents bone destruction in collagen‐induced arthritis
Sims, N. A., Green, J. R., Glatt, M., Schlicht, S., Martin, T. J., Gillespie, M. T., & Romas, E. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20382 · Cited by 128
NF-κB inducing kinase: A key regulator in the immune system and in cancer
Thu, Y. M., & Richmond, A. J. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.06.002 · Cited by 146
“certain arthritis models [101,102].”
Osteoprotegerin: a link between osteoporosis and arterial calcification?
Hofbauer, L. C., & Schoppet, M. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05494-0 · Cited by 133
Glucocorticoid-Induced Osteoporosis: Summary of a Workshop
Canalis, E., & Giustina, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8066 · Cited by 126
Inhibitory Immunoglobulin-Like Receptors LILRB and PIR-B Negatively Regulate Osteoclast Development
Mori, Y., Tsuji, S., Inui, M., Sakamoto, Y., Endo, S., Ito, Y., Fujimura, S., Koga, T., Nakamura, A., Takayanagi, H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4742 · Cited by 125
Lee, M. S., Kim, H. S., Yeon, J.-T., Choi, S.-W., Chun, C. H., Kwak, H. B., & Oh, J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804314 · Cited by 125
“sors (15), they also inhibit osteoclast differentiation through inhi-”
BackgroundKim, Y.-M., Kim, Y.-M., Lee, Y. M., Kim, H.-S., Kim, J. D., Choi, Y., Kim, K.-W., Lee, S.-Y., & Kwon, Y.-G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109434200 · Cited by 125
Takahashi, N., Udagawa, N., Takami, M., & Suda, T. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1/50109-8 · Cited by 161
Estrogens in rheumatoid arthritis; the immune system and bone
Islander, U., Jochéms, C., Lagerquist, M. K., Forsblad‐d’Elia, H., & Carlsten, H. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.05.018 · Cited by 148
Bolon, B. N., Stolina, M., King, C., Middleton, S. C., Gasser, J., Zack, D. J., & Feige, U. (2010) · BioMed Research International · doi:10.1155/2011/569068 · Cited by 135
Self-citationParathyroid Hormone-induced Bone Resorption Does Not Occur in the Absence of Osteopontin
Ihara, H., Denhardt, D. T., Furuya, K., Yamashita, T., Muguruma, Y., Tsuji, K., Hruska, K. A., Higashio, K., Enomoto, S., Nifuji, A., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010938200 · Cited by 122
Effects of Interleukin-17A on Osteogenic Differentiation of Isolated Human Mesenchymal Stem Cells
Osta, B., Lavocat, F., Eljaafari, A., & Miossec, P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00425 · Cited by 138
The molecular mechanism of osteoclastogenesis in rheumatoid arthritis.
Udagawa, N., Kotake, S., Kamatani, N., Takahashi, N., & Suda, T. (2002) · Arthritis Research · doi:10.1186/ar431 · Cited by 138
Modulation of osteoclast formation
Quinn, J. M. W., & Gillespie, M. T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.076 · Cited by 142
Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease
Boyce, B. F., Schwarz, E. M., & Xing, L. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000231913.32364.32 · Cited by 122
Zaiss, M. M., Sarter, K., Hess, A., Engelke, K., Böhm, C., Nimmerjahn, F., Voll, R., Schett, G., & David, J. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27535 · Cited by 122
Rheumatoid Arthritis in the View of Osteoimmunology
Auréal, M., Machuca‐Gayet, I., & Coury, F. (2020) · Biomolecules · doi:10.3390/biom11010048 · Cited by 135
Gaffen, S. L. (2004) · Arthritis Research · doi:10.1186/ar1444 · Cited by 131
Nagasawa, T., Kiji, M., Yashiro, R., Hormdee, D., Lu, H., Kunze, M., Suda, T., Koshy, G., Kobayashi, H., Oda, S., et al. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00185.x · Cited by 151
Schett, G., & Teitelbaum, S. L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090533 · Cited by 119
Ohshiba, T., Miyaura, C., Inada, M., & Itô, A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600858 · Cited by 126
Interferon‐β‐induced miR‐155 inhibits osteoclast differentiation by targeting SOCS1 and MITF
Zhang, J., Zhao, H., Chen, J., Xia, B., Jin, Y., Wei, W., Shen, J., & Huang, Y. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.06.047 · Cited by 133
Differential cytokine expressions affect the severity of peri‐implant disease
Duarte, P. M., de Mendonça, A. C., Máximo, M. B. B., Santos, V. R., Bastos, M. F., & Nociti, F. H. (2009) · Clinical Oral Implants Research · doi:10.1111/j.1600-0501.2008.01680.x · Cited by 127
The pathophysiology of bone disease in gastrointestinal disease
Bernstein, C. N., & Leslie, W. D. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200308000-00004 · Cited by 120
Osteoimmunology in Periodontitis and Orthodontic Tooth Movement
Alghamdi, B., Jeon, H. H., Ni, J., Qiu, D., Liu, A., Hong, J. J., Ali, M., Wang, A., Troka, M. E., & Graves, D. T. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00774-x · Cited by 147
Min, J.-K., Kim, Y.-M., Kim, Y.-M., Kim, E.-C., Gho, Y. S., Kang, I.-J., Lee, S.-Y., Kong, Y.-Y., & Kwon, Y.-G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300539200 · Cited by 118
Self-citationBone loss in inflammatory arthritis: mechanisms and treatment strategies
Walsh, N. C., & Gravallese, E. M. (2004) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000127824.42507.68 · Cited by 124
Review: Immune cells and mediators of inflammatory arthritis
Schett, G. A. (2008) · Autoimmunity · doi:10.1080/08916930701694717 · Cited by 134
Wakkach, A., Mansour, A., Dacquin, R., Coste, E., Jurdic, P., Carle, G. F., & Blin-Wakkach, C. (2008) · Blood · doi:10.1182/blood-2008-01-132787 · Cited by 118
Mathematical Modeling of Spatio-Temporal Dynamics of a Single Bone Multicellular Unit
Ryser, M. D., Nigam, N., & Komarova, S. V. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081229 · Cited by 131
The RANKL/OPG system and bone mineral density in patients with chronic liver disease
Moschen, A. R., Kaser, A., Stadlmann, S., Millonig, G., Kaser, S., Mühllechner, P., Habior, A., Graziadei, I. W., Vogel, W., & Tilg, H. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.05.034 · Cited by 129
“c Time between OPG/sRANKL and BMD assessment was 7 (28) [0–112] days detection a mouse anti-human OPG monoclonal antibody (mAb) was purchased from Imgenex (San Diego, CA).”
BackgroundMethodSaidenberg-Kermanac'h, N., Corrado, A., Lemeiter, D., deVernejoul, M. C., Boissier, M. C., & Cohen-Solal, M. E. (2004) · Bone · doi:10.1016/j.bone.2004.07.004 · Cited by 117
“RANKL secretion by activated T cells [17 18] contributes to the pathophysiology of inflammation and destruction in RA, as shown in murine models where OPG inhibits bone erosions but not inflammation [11,19].”
BackgroundPacifici, R. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.05.027 · Cited by 115
Impacts of Psychological Stress on Osteoporosis: Clinical Implications and Treatment Interactions
Kelly, R. R., McDonald, L. T., Jensen, N. R., Sidles, S. J., & LaRue, A. C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00200 · Cited by 115
Giuliani, N., Colla, S., & Rizzoli, V. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.03.015 · Cited by 128
“In pathophysiological conditions, such as arthritis, activated T cells are capable of regulating bone loss through the expression of RANKL [24,25].”
BackgroundInflammatory Mediators as Essential Elements in Bone Remodeling
Goldring, S. R. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-1049-y · Cited by 122
“Targeting this osteoclast-inducing factor in models of inflammatory arthritis by treating animals with OPG (the soluble receptor that inhibits RANKL activity) results in marked suppression of bone erosions [24, 25].”
BackgroundGenetic deficiency of Syk protects mice from autoantibody‐induced arthritis
Jakus, Z., Simon, E., Balázs, B., & Mócsai, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27438 · Cited by 113
Bacteria Induce Osteoclastogenesis via an Osteoblast-Independent Pathway
Jiang, Y., Mehta, C. K., Hsu, T.-Y., & Alsulaimani, F. F. (2002) · Infection and Immunity · doi:10.1128/iai.70.6.3143-3148.2002 · Cited by 115
Delmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.02.002 · Cited by 129
Bamias, G., Siakavellas, S. I., Stamatelopoulos, K., Chryssochoou, E., Papamichael, C. M., & Sfikakis, P. P. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.014 · Cited by 119
Osteoclast formation and resorption
Lerner, U. H. (2000) · Matrix Biology · doi:10.1016/s0945-053x(00)00052-4 · Cited by 154
Juarranz, Y., Abad, C., Martínez, C., Arranz, A., Gutiérrez‐Cañas, I., Rosignoli, F., Gomariz, R. P., & Leceta, J. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1779 · Cited by 120
Amelioration of rat adjuvant‐induced arthritis by Met‐RANTES
Shahrara, S., Proudfoot, A. E. I., Woods, J. M., Ruth, J. H., Amin, M. A., Park, C. C., Haas, C. S., Pope, R. M., Haines, G. K., Zha, Y. Y., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21033 · Cited by 119
O' Gradaigh, D., Ireland, D., Bord, S., & Compston, J. E. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.008458 · Cited by 111
Crotti, T. N., Dharmapatni, A. A. S. S. K., Alias, E., & Haynes, D. R. (2015) · Journal of Immunology Research · doi:10.1155/2015/281287 · Cited by 117
NF-κB–inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis
Aya, K., Alhawagri, M., Hagen-Stapleton, A., Kitaura, H., Kanagawa, O., & Veis Novack, D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23763 · Cited by 112
Osteoprotegerin in the Inner Ear May Inhibit Bone Remodeling in the Otic Capsule
Zehnder, A. F., Kristiansen, A. G., Adams, J. C., Merchant, S. N., & McKenna, M. J. (2005) · The Laryngoscope · doi:10.1097/01.mlg.0000150702.28451.35 · Cited by 118
Herrak, P., Görtz, B., Hayer, S., Redlich, K., Reiter, E., Gasser, J., Bergmeister, H., Kollias, G., Smolen, J. S., & Schett, G. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20384 · Cited by 110
New Insights Into Osteoclast Biology
McDonald, M. M., Kim, A. S., Mulholland, B. S., & Rauner, M. (2021) · JBMR Plus · doi:10.1002/jbm4.10539 · Cited by 133
“Stromal cells, osteoblasts, and osteocytes in the bone microenvironment are critical regulators of osteoclast differentiation because they are the main producers of M-CSF and RANKL,((3,35,36)) although immune cells can also induce their expression during pathological conditions such as hormone deficiency or inflammati…”
BackgroundPromising bone-related therapeutic targets for rheumatoid arthritis
Choi, Y., Arron, J. R., & Townsend, M. J. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.175 · Cited by 125
Metadata
- Authors
- Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E. R., Van, G., Nguyen, L. T., Ohashi, P. S., Lacey, D. L., Fish, E., Boyle, W. J., & Penninger, J. M.
- Affiliations
- Amgen (Canada) (CA)
- Amgen (United States) (US)
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- ORCID
- Venue
- Nature
- Published
- 1999-11
- Volume
- 402
- Issue
- 6759
- Pages
- 304-309
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1677043489
- Cited by
- 1,856
- References
- 24
- Citations by year
- 2026: 17 · 2025: 33 · 2024: 36 · 2023: 33 · 2022: 25 · 2021: 36 · 2020: 47 · 2019: 43 · 2018: 38 · 2017: 59 · 2016: 64 · 2015: 82 · 2014: 80 · 2013: 85 · 2012: 77
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Cystic Fibrosis Foundation
- U.S. Public Health Service
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- osteoprotegerin ligand, osteoprotegerin, RANK, activated T cells, adjuvant-induced arthritis, bone loss, osteoclastogenesis, joint destruction, cartilage destruction, T cell activation, bone remodeling, osteoclasts
- MeSH terms
- Animals, Arthritis, Experimental, Bone and Bones, Bone Resorption, Carrier Proteins, Cartilage, Cells, Cultured, Glycoproteins, Humans, Lymphocyte Activation, Membrane Glycoproteins, Mice, Inbred C57BL, Rats, Inbred Lew, T-Lymphocytes, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Coculture Techniques, Mice, Rats, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.